| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the second in a three part report series on Alignment Among Public Formularies in Canada
| Patented Medicine Prices Review Board Canada | news releases
Federal Minister of Health tables the 2019 Annual Report of the Patented Medicine Prices Review Board
| Patented Medicine Prices Review Board Canada | news releases
Canada still among top 10 OECD countries in terms of access to new drugs
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2020.
| Patented Medicine Prices Review Board Canada | news releases
Annual expenditures on drugs in public plans exceeded $12 billion in 2018-19
| Patented Medicine Prices Review Board Canada | news releases
Today, the PMPRB, under the National Prescription Drug Utilization Information System (NPDUIS) initiative, released a chartbook on the market for oncology medicines in Canada.
| Patented Medicine Prices Review Board Canada | news releases
PMPRB completes five year consultative process to strengthen and modernize its regime with release of new Guidelines
| Patented Medicine Prices Review Board Canada | news releases
The PMPRB is holding public consultations on its proposed new pricing Guidelines
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology treatments made up over a third of the more than 5,500 new drugs in all phases of clinical trials in 2019.
| Patented Medicine Prices Review Board Canada | news releases
New report shows that high-cost specialty medicines account for an ever-increasing proportion of new treatments coming to market
